Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

From Pfizer to AstraZeneca and the Omnicom-IPG Merger, the industry has seen a number of executive moves during this year.

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.57 which represents a slight increase of $1.48 or 1.62% from the prior close of $91.09. The stock opened at $90.92 and ...

Cohen & Steers Income Opportunities REIT, Inc. ("CNSREIT") announced today its acquisition of Bridgepointe Shopping Center, an open-air community shopping center in San Mateo, California. The ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

This growth, in large part driven by tech and the continuing AI revolution, has surprised value investors and professional ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

Note to readers: The Daily Edition will not be published Dec. 23 through Jan. 1. Look for it again in your inbox on Jan. 2.

The cyberattack happened earlier this year, the company disclosed. Other industry news comes from CVS, Gilead, Ionis, and more.

The global cardiometabolic drugs market is projected to grow from US$ 50 billion in 2021 to over US$ 70 billion by 2032, with a CAGR of 4% to 5%. Sales are expected to surpass US$ 55 billion by 2022, ...